FDA approves Ranluspec as biosimilar to Lucentis

The FDA approved Ranluspec, an interchangeable biosimilar referencing Lucentis, as a treatment for vision-threatening retinal diseases, according to a press release from Lupin.

Raccontata dahealio.com